Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
Vaccitech Limited and the University of Oxford announce initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in…
Read More...
Read More...
